Abstract LB-386: MicroRNA-164a activates the Wnt pathway to promote breast cancer metastasis

• Published in: Cancer research (Chicago, Ill.) Vol. 78; no. 13_Supplement; p. LB-386
• Main Authors: Kantono, Melvin, Sun, Wei, Guo, Beichu
• Format: Journal Article
• Language: English
• Published: 01-07-2018
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2018-LB-386

Breast cancer is the most common type of malignant tumor among women, and is the second leading cause of cancer-related death in women. The triple negative breast cancer (TNBC) remains is one of the major contributors of breast cancer mortality. TNBCs are a type of aggressive breast cancer that exhibits a high rate of distant metastasis and poor survival compared with other breast cancer subtypes. Although immunotherapy with PD-1 and PD-L1 blockade have achieved durable responses in a number of tumors, including TNBC. However, the overall response rates were low. Thus, elucidating the mechanisms responsible for tumor metastasis and the interaction of tumor cells with their microenvironments is critical for developing effective therapeutic approaches to treat metastatic breast cancer. Our results suggest that miR-146 can induce oncogenic transformation and tumor metastasis in the context of breast cancer. We found that miR-146a is highly expressed in TNBC cells, and is critical for the expansion of tumor-initiating cells in breast cancer growth and metastasis. Our preliminary data further indicate that miR-146a promotes breast tumorigenesis by targeting negative regulators of Wnt pathway, which is frequently altered in various tumors. The goal of this study to develop novel therapeutic approaches that could ultimately lead to effective treatment for breast cancer, particularly TNBC.
Citation Format: Melvin Kantono, Wei Sun, Beichu Guo. MicroRNA-164a activates the Wnt pathway to promote breast cancer metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-386.